Innoviva Inc at Cantor Fitzgerald Global Healthcare Conference Transcript
Hi, good day, my name is Louise Chen, I'm the large-cap pharma, biopharma, biotech analyst here at Cantor, very pleased to have with us today the CEO of Innoviva, Pavel Raifeld.
Questions & Answers
So Pavel, to start, could you tell us a little bit about your company and also what your strategic vision is over the next three to five years?
Sure, hi. Thank you very much, Louise, and it's really a pleasure to be here and to see everyone. So Innoviva is a very, very interesting company and a company I'm very passionate and excited about as one would expect.
So we started out as a royalty company, our background was that a number of years ago, we created a technology, which we then partnered out to GSK. And we've been receiving very considerable royalties to the tune of say, [quarter of a billion dollar] of cash flow a year from that.
And so over the past three years, we
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
